

## **Resistance of endothelial cells to SARS-CoV-2 infection *in vitro***

\*Blerina Ahmetaj-Shala, BSc, MSc, PhD<sup>1</sup>, \*Thomas P. Peacock BSc, PhD<sup>2</sup>, Laury Baillon BSc<sup>2</sup>, Olivia C. Swann, BSc<sup>2</sup>, Hime Gashaw, BSc<sup>1</sup>, \*Wendy S. Barclay, BSc, PhD<sup>2</sup> and \*Jane A. Mitchell, BSc, PhD<sup>1</sup>.

\*BA-S and TPP contributed equally to the study and share first author.

\*WSB and JAM contributed equally to the study and share senior author.

**Running title:** COVID-19, Endothelial cells and SARS-CoV-2 infection

### **Affiliations:**

<sup>1</sup>National Heart and Lung Institute, Imperial College London, London, SW7 2AZ, UK.

<sup>2</sup>Department of Infectious Diseases, Imperial College London, London, UK, W2 1PG, UK.

### **Corresponding author details:**

Blerina Ahmetaj-Shala: [b.ahmetaj@imperial.ac.uk](mailto:b.ahmetaj@imperial.ac.uk)

**Abstract:**

**Rationale:** The secondary thrombotic/vascular clinical syndrome of COVID-19 suggests that SARS-CoV-2 infects not only respiratory epithelium but also the endothelium activating thrombotic pathways, disrupting barrier function and allowing access of the virus to other organs of the body. However, a direct test of susceptibility to SARS-CoV-2 of authentic endothelial cell lines has not been performed.

**Objective:** To determine infectibility of primary endothelial cell lines with live SARS-CoV-2 and pseudoviruses expressing SARS-CoV-2 spike protein.

**Methods and Results:** Expression of ACE2 and BSG pathways genes was determined in three types of endothelial cells; blood outgrowth, lung microvascular and aortic endothelial cells. For comparison nasal epithelial cells, Vero E6 cells (primate kidney fibroblast cell line) and HEK 293T cells (human embryonic kidney cells) transfected with either ACE2 or BSG were used as controls. Endothelial and Vero E6 cells were treated with live SARS-CoV-2 virus for 1 hour and imaged at 24 and 72 hours post infection. Pseudoviruses containing SARS-CoV-2, Ebola and Vesicular Stomatitis Virus glycoproteins were generated and added to endothelial cells and HEK 239Ts for 2 hours and infection measured using luminescence at 48 hours post infection. Compared to nasal epithelial cells, endothelial cells expressed low or undetectable levels of ACE2 and TMPRSS2 but comparable levels of BSG, PPIA and PPIB. Endothelial cells showed no susceptibility to live SARS-CoV-2 or SARS-CoV-2 pseudovirus (but showed susceptibility to Ebola and Vesicular Stomatitis Virus). Overexpression of ACE2 but not BSG in HEK 239T cells conferred SARS-CoV-2 pseudovirus entry. Endothelial cells primed with IL-1 $\beta$  remained resistant to SARS-CoV-2.

**Conclusion:** Endothelial cells are resistant to infection with SARS-CoV-2 virus, in line with relatively low levels of ACE2 and TMPRSS2, suggesting that the vascular dysfunction and thrombosis seen in severe COVID-19 is a result of factors released by adjacent infected cells (e.g. epithelial cells) and/or circulating, systemic inflammatory mediators.

## Introduction:

COVID-19 represents one of the most important clinical challenges the scientific community has faced in recent memory. In the absence of an effective vaccine and no clear evidence that prior infection confers long-term immunity<sup>1</sup>, there is an urgent unmet need to understand disease pathology and to establish therapeutics that mitigate COVID-19 severity and reduce associated lethality<sup>2</sup>. SARS-CoV-2 spike protein binds to host cells via ACE2<sup>3</sup> and viral entry is facilitated by the cell-surface protease TMPRSS2<sup>3</sup> or lysosomal cysteine proteases cathepsin B/L (CTSB, CTSL)<sup>3</sup>. It has also been suggested that, as an alternative pathway, SARS-CoV-2 binds to cells via BSG (Basigin; also known as CD147 or EMMPRIN)<sup>4, 5</sup>, although firm evidence for BSG as a standalone receptor for SARS-CoV-2 remains the subject of investigation with a recent study noting no ‘direct’ binding of SARS-CoV-2 spike protein to BSG<sup>6</sup>.

Initial infection with SARS-CoV-2 occurs via the respiratory epithelium<sup>7</sup>. In most people symptoms are mild but in a significant minority COVID-19 progresses to severe disease and in those that ‘recover’ symptoms can persist leading to a syndrome recently defined as ‘long-COVID’<sup>8</sup>. In severe COVID-19 and in long-COVID multiple organs including the cardiovascular system are affected<sup>9, 10</sup>. This secondary thrombotic/vascular clinical syndrome of COVID-19 suggests that SARS-CoV-2 infects not only respiratory epithelium but also the endothelium disrupting barrier function and allowing dissemination to other organs of the body<sup>11</sup>. This notion is supported by early reports showing that SARS-CoV-2 infects endothelial cells *in vitro*<sup>12</sup> and *in vivo*<sup>13</sup>. However, for the *in vitro* studies performed to date, non-physiological cell lines were used and for *in vivo* studies serious concerns have been raised regarding the validity of the interpretation of data and the resulting conclusions<sup>14</sup>. Currently, therefore, it is not clear if endothelial cells are permissive to SARS-CoV-2 or not. Only by addressing this can biomarkers, mechanisms and therapeutic targets directed at the vasculopathy and thrombosis associated with COVID-19 be established.

We have recently shown that blood outgrowth endothelial cells express relatively low levels of ACE2 and TMPRSS2 but high levels of BSG and speculated that if endothelial cells are infected by SARS-CoV-2, BSG, rather than ACE2, would act as the receptor for viral entry<sup>15</sup>. However, in our previous work and that of others, a direct test of susceptibility to SARS-CoV-2 of authentic endothelial cell lines has not been performed.

Here we have performed the first infection study using primary endothelial cell lines with live SARS-CoV-2 and pseudoviruses (PV) expressing SARS-CoV-2 spike protein. Specifically, we used (i) blood outgrowth endothelial cells, selected for their utility as biomarkers and in personalised medicine, (ii) lung microvascular endothelial cells, selected based on likely points of access of the virus and (iii) aortic endothelial cells, selected as representative of systemic vessels. For comparison we used positive control cells including nasal epithelial cells, Vero E6 cells (primate kidney fibroblast cell line) and HEK 293T cells (human embryonic kidney cells) transfected with either ACE2 or BSG.

## **Methods:**

### **Biosafety statement**

All work performed was approved by the local genetic manipulation (GM) safety committee of Imperial College London, St. Mary's Campus (centre number GM77), and the Health and Safety Executive of the United Kingdom, under reference CBA1.77.20.1.

### **Cells**

Primary human endothelial cell lines including blood outgrowth endothelial cells (obtained in house<sup>16</sup>), lung microvascular endothelial cells and aortic endothelial cells (obtained from Lonza; UK) were used in this study. In each case cells from 3 separate donors/ per endothelial cell type were used except for qPCR studies using blood outgrowth endothelial cells where cells from 2 donors were used. Nasal epithelial cells were obtained from Promocell (Germany) and grown in submerged culture and differentiated nasal epithelial cells (MucilAir™) were obtained from Epithelix (Switzerland) and grown in air-liquid interface culture.

African green monkey (Vero E6) cells (ATCC) and human embryonic kidney cells (293T) - 293T(ATCC) were cultured in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% foetal bovine serum (FBS), 1% non-essential amino acids (NEAA) and 1% penicillin-streptomycin (P/S; Gibco). HEK 293T-ACE2 cells were produced as previous described<sup>17</sup> (Figure 3, Supplementary Figure 2) and maintained in HEK 293T media supplemented with 1 µg/ml of puromycin. For transient transfections HEK 293T cells seeded in 10cm<sup>2</sup> plates were transfected with 1 µg of empty pCAGGs vector, pCAGGs-ACE2-FLAG, or pCAGGS-BSG (synthesised by GeneArt; ThermoFisher), 24 hours later cells were transferred to 96 well plates or lysed for western blot analysis. Aortic and blood outgrowth endothelial cells were maintained on uncoated plates in Endothelial Cell Growth Medium-2 (EGM-2; Lonza, UK), while lung microvascular cells were maintained on uncoated plates in Microvascular Endothelial Cell Growth Medium-2 (EGM-2 MV; Lonza, UK). Nasal epithelial cells were maintained in Airway Epithelial Growth Media (Promocell, Germany) while MucilAir™ nasal epithelial cells were maintained in MucilAir Culture Medium (Epithelix, Switzerland). All media for endothelial and epithelial cells were supplemented with their appropriate BulletKits, 10% FBS (Biosera, UK) and 1% P/S (Gibco, UK). Treatment protocols (except for those using MucilAir™ cells) were conducted using 'treatment media' (EGM-2 medium (Promocell, Germany) supplemented with 2% FBS (Promocell, Germany) and 1% P/S

(Gibco, UK). For all experiments, endothelial and nasal epithelial cells were used between passage 4-6. All cells were maintained at 37°C, 5% CO<sub>2</sub>.

### **RT-qPCR**

Endothelial and nasal epithelial cells were plated in duplicate wells on uncoated 6 well plates in their cell-specific media (see above) and grown to confluence. The day before RNA extraction media was replaced with the treatment media. After 24 hours cells were washed with phosphate-buffered saline (PBS), duplicate wells combined and RNA extracted using RNeasy Extraction kit (Qiagen, UK). RNA was converted to cDNA using the iScript cDNA synthesis kit (BioRad, CA, USA). Gene expression levels were determined using a TaqMan expression assay, with the following primers (ThermoScientific, UK); ACE2 (Hs01085333\_m1), TMPRSS2 (Hs00237175\_m1), BSG (Hs00936295\_m1), PPIA (Hs04194521\_s1) and PPIB (Hs00168719\_m1). Genes were quantified relative to housekeeping genes (GAPDH and 18S) by the comparative Ct method.

### **SARS-CoV-2 live virus infection studies**

For infection studies with Mucilair human airway epithelial cells, SARS-CoV-2/England/IC19/202 (IC19)<sup>18</sup> was diluted in serum-free DMEM, 1% NEAA, 1% P/S to a multiplicity of infection (MOI) of 0.1. Inoculum was added to the exposed apical face of the cells and incubated at 37°C for 1 hour. Inoculum was then removed and cells maintained as described above. At each timepoint in the infection, virus was collected from the apical surface of the cultures by washing with pre-warmed PBS for 10 minutes at 37°C and quantified by plaque assay on Vero E6 cells. Briefly, cells were washed with PBS then serial dilutions of inoculum, diluted in serum-free DMEM, 1% NEAA, 1% P/S, were overlaid onto cells for one hour at 37°C. Inoculum was then removed and replaced with SARS-CoV-2 overlay media (1x minimal essential media (MEM), 0.2% w/v bovine serum albumin, 0.16% w/v NaHCO<sub>3</sub>, 10mM HEPES, 2mM L-Glutamine, 1x P/S, 0.6% w/v agarose). Plates were incubated for 3 days at 37°C before overlay was removed and cells were stained for 1 hour at RT in crystal violet solution.

For infection studies using endothelial cells, cells were plated on sterile round 16mm diameter coverslips in 12 well plates (5x10<sup>4</sup> cells/well) without coating. Their usual media (see above) was added and cells allowed to settle overnight. Control Vero E6 cells were plated to achieve

approximately 80% confluency. The following day, media was removed and cells washed in PBS. For endothelial cells, treatment media was added either alone (untreated/ control) or with IL-1 $\beta$  (10ng/ml) for 3 hours. Meanwhile IC19<sup>18</sup> was diluted in serum free DMEM, 1%NEAA, 1% P/S, to a multiplicity of infection (MOI) of 0.1. After 3 hours treatment with either media alone or IL-1 $\beta$ , media was replaced with IC19 containing inoculum and incubated at 37°C for 1 hour. Inoculum was then removed and replaced with treatment media and cells were maintained until 24, 48 or 72 hours post-infection. At the appropriate timepoint, treatment media was removed and cells were fixed in 4% paraformaldehyde (PFA) for 30 minutes. PFA was removed with three washes of PBS. Cover slips were dehydrated in an ethanol series and stored in 100% ethanol at -20°C until further processing.

### **Fluorescent imaging**

For fluorescent imaging, infected cells on cover slips were first rehydrated in an ethanol series. Cells were permeabilised in PBS with 0.5% triton-X for 10 minutes, washed 3x in PBS, then blocked in PBS with 2% bovine serum albumin (BSA) and 0.1% tween (blocking buffer). Primary antibodies were diluted 1:1000 in blocking buffer and incubated on cells at room temperature for 1 hour. Primary antibodies used were against spike protein (S) (Mouse monoclonal, Gene tex (1A9)) or nucleoprotein (N) (Rabbit monoclonal, Sino Biological). Following 3x PBS washes, cells were incubated with secondary antibodies (anti-rabbit 488, anti-mouse 594) diluted 1:500 and DAPI (diluted 1 in 1000) in PBS with 2% BSA at room temperature for 1 hour in the dark. Stained cover slips were mounted on glass slides in ProLong gold antifade mounting medium (Invitrogen). Images were acquired using either a Zeiss Axiovert 135 TV microscope (Figure 2B) or a Zeiss Cell Observer widefield microscope (Figure 2C). All images were analysed and prepared using FIJI software<sup>19</sup>. For each cell type/condition slides were first reviewed by eye before representative fields of view were captured. Images were captured and processed in an identical manner across each experiment to ensure fair comparison either as a single plane of focus (Figure 2B) or as Z stacks presented as maximum intensity projections (Figure 2C). For quantitative analysis, all images were blinded and independently scored between 1-5, where 1= 0-2, 2= 3-5, 3=6-8, 4= 9-10 and 5=>10 nucleocapsid stained cells.

### **Lentiviral pseudovirus studies**

Lentiviral pseudotypes were generated as previous described<sup>17</sup>. Briefly, dishes of HEK 293T cells were co-transfected with 1 µg of HIV packaging plasmid, pCAGGs-GAGPOL, 1.5 µg of luciferase reporter genome construct, pCSLW, and 1 µg of the named envelope proteins in pcDNA3.1. Media was replaced at 24 hours to remove transfection reagents and plasmids and then pseudovirus-containing supernatants were harvested at 48 and 72 hours post-transfection. Pooled supernatant was then passed through a 0.45 µm filter, aliquoted and frozen at -80°C.

Cells were plated in duplicate wells in 96 well plates (1x10<sup>4</sup>/ well) in their own media and allowed to settle overnight in their appropriate growth media. The next day media was removed and replaced with treatment media alone (untreated/ control) or with IL-1β (10ng/ml) for 3 hours. Media was then removed and cells were treated with pseudovirus containing-supernatants added for 2 hours before replacing with treatment media. Cells were then left for 48 hours before lysis with cell culture lysis buffer (Promega). Luminescence was read on a FLUOstar Omega plate reader (BMF Labtech) using the Luciferase Assay System (Promega).

### **Western Blot**

HEK 293Ts transfected with different potential receptors or empty vector were lysed 24 hours post-transfection with RIPA buffer (150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50mM TRIS, pH 7.4) supplemented with an EDTA-free protease inhibitor cocktail tablet (Roche). Cell lysates were then mixed with 4x Laemmli sample buffer (Bio-Rad) with 10% β-mercaptoethanol. Protein samples were run on a 4-15% mini-PROTEAN TGX SDS-PAGE gel (Bio-Rad) and transferred onto a nitrocellulose membrane by semi-dry transfer. Membranes were probed with the primary antibodies: mouse anti-FLAG (Sigma: F1804); mouse anti-tubulin (abcam; ab7291); and rabbit anti-CD147 (abcam; ab108308). Near infra-red (NIR) secondary antibodies, IRDye® 680RD Goat anti-mouse (abcam; ab216776) and IRDye® 800CW Goat anti-rabbit (abcam; ab216773)) were subsequently used to detect primary antibodies. Western blots were visualised using an Odyssey Imaging System (LI-COR Biosciences).

### **IL-6 and IL-8 ELISA**

IL-6 and IL-8 was measured using duo set ELISAs from R&D Systems according to manufactures instructions.

### **Data analysis:**

All data were analysed on GraphPad Prism v8 and are shown as individual data points and/or mean +/- standard error of the mean (SEM) for samples as described in the figure legends.

## Results:

In our recent study, where we performed a systematic analysis of online transcriptomic databases in endothelial cells and nasal and bronchial epithelium, we found endothelial cells express relatively low levels of ACE2 and TMPRSS2 but high levels of BSG and PPIA/PPIB (also known as cyclophilin A/B; CypA/B)<sup>15</sup>. PPIA and PPIB are potential co-ligands for pathogen entry to cells via the BSG pathway. Here we have validated and extended our earlier studies by measuring gene expression using qPCR in blood outgrowth endothelial cells, lung microvascular endothelial cells, aortic endothelial cells and, for comparisons, nasal epithelium. In line with our previous observations, compared to nasal epithelial cells, endothelial cells expressed low or undetectable levels of ACE2 and TMPRSS2 but comparable levels of BSG, PPIA and PPIB, (Figure 1; Supplementary Table 1). These observations suggest that if endothelial cells are susceptible to infection with SARS-CoV-2 it may occur in an ACE2-independent pathway, for example via the putative BSG receptor pathway.

Next, using experimental conditions where nasal epithelial cells grown in liquid: air interface culture were highly susceptible to infection with SARS-CoV-2 (Figure 2A), we inoculated endothelial cells and, in parallel, Vero E6 cells, with live SARS-CoV-2. Initially we performed pilot studies using blood outgrowth endothelial cells and Vero E6 cells incubated for 24 hours after a 1 hour inoculation (Figure 2B). These were followed by separate experiments using each of the 3 endothelial cell types incubated for up to 72 hours post inoculation with live SARS-CoV-2 (Figure 2C). In both studies by indirect immunofluorescence microscopy (IF) we could see cells staining positive for viral antigens (nucleocapsid protein or spike) in Vero E6 cells, indicating virus replication, but not in the endothelial cell types at any of the time points tested (Figures 2B and C; Supplementary Figure 1). These results suggest that endothelial cells have a block to SARS-CoV-2 infection, however it is not clear whether this block is at virus entry or upon a post-entry step in replication.

To investigate whether the block to virus infection was at entry we performed studies using pseudoviruses based on lentiviral vectors, expressing SARS-CoV-2 spike protein and, by way of positive controls for viral infectability, pseudovirus expressing the glycoproteins of Vesicular Stomatitis Virus (VSV-G), which shows broad cell-type tropism and Ebola, which has previously been shown to efficiently infect endothelial cells<sup>20</sup>. As with the virus infection, endothelial cells were not susceptible to SARS-CoV-2 spike-mediated entry, showing similar levels of luciferase signal as bald pseudovirus expressing no viral glycoprotein (Figure 3A),

but were found to be susceptible to pseudovirus expressing Ebola glycoprotein and VSV-G (Figure 3B and D). Furthermore, HEK 293T cells stably expressing ACE2 showed high susceptibility to all 3 pseudoviruses. These observations are in line with low level ACE2 expression across our endothelial cell lines and suggest that the high levels of BSG expression do not compensate to allow infection with SARS-CoV-2. To address this assumption, we investigated SARS-CoV-2 pseudovirus entry into HEK 293T cells transiently transfected with either ACE2 or BSG (successful transfection was confirmed using western blot analysis; Supplementary Figure 2). From this data it was clear that transfected ACE2 but not BSG efficiently mediated SARS-CoV-2 pseudovirus entry (Figure 3D).

Finally, to investigate how an inflammatory environment might facilitate virial entry of SARS-CoV-2 into endothelial cells additional protocols were performed where cells were primed with IL-1 $\beta$ . At 24 hours IL-1 $\beta$  primed endothelial cells released increased levels of IL-6 and IL-8, demonstrating a positive inflammatory response (Supplementary Figure 3). However, under these conditions each of the endothelial cell types remained resistant to SARS-CoV-2 spike mediated entry (Figure 4A and B).

## Discussion:

There is mounting speculation that the vascular and thrombotic sequela associated with severe COVID-19 is a result of endothelial cell infection with SARS-CoV-2. However, there is currently no direct evidence to support this idea. In response to this, we have used standard virology protocols to directly address the question of '*are endothelial cells permissive to infection with SARS-CoV-2 virus?*' We have used 3 carefully selected primary endothelial cells lines from 3 separate donors for each line. The results were unambiguous and interpreted alongside data from robust positive control cells infect with live virus and pseudoviruses. Taken together our data suggest that endothelial cells are not susceptible to infection with SARS-CoV-2 because they express insufficient levels of ACE2. Our findings that endothelial cells remain non-susceptible to infection with SARS-CoV-2 despite expressing high levels of BSG suggests that the BSG pathway is not a functional entry pathway for SARS-CoV-2 in endothelial cells. This idea is confirmed from our studies using HEK 293T cells transiently transfected with BSG which, in contrast to ACE2, did not make cells susceptible to SARS-CoV-2 spike-mediated entry.

Our results showing that endothelial cells are not susceptible to the SARS-CoV-2 virus suggests that the vascular dysfunction and thrombosis seen in severe COVID-19 is a result of factors released by adjacent infected cells (e.g. epithelial cells) and/or circulating, systemic inflammatory mediators. In addition, it is possible that SARS-CoV-2 virus may act as an inflammatory stimulus either via the spike protein or other structural components without the requirement for conventional binding, cell entry or virus replication<sup>21</sup>. Our study does not rule out this possibility and this remains the subject of further investigation. Our work also suggests that where viremia occurs in COVID-19, SARS-CoV-2 passes through the endothelium facilitated by loss of barrier function, as a result of local inflammation at the site of infection.

While we have worked to the highest standards with empirical virology protocols, there are limitations in our approach, and we cannot definitively conclude that endothelial cells are non-susceptible to infection by SARS-CoV-2 in some individuals or in some highly specific conditions *in vivo*. This is because the assay systems we used did not take account of critical factors present in at risk populations and/or at the site of inflammation. In an attempt to take account of basic inflammatory conditions we performed experiments in cells primed with IL-1 $\beta$ , which did not confer infectability to any of our endothelial lines. However, as we find more about the complex mix of inflammatory mediators present in the lung and circulation in

COVID-19 and the specific biological factors that predispose certain groups of individuals to severe disease, these can be recapitulated within *in vitro* assay systems. Nonetheless what our study does prove is that if endothelial cells are susceptible to SARS-CoV-2 at some distant point in the natural history of COVID-19, the pathways of viral entry are more complex than for airway epithelium.

### **Acknowledgements:**

We thank the FILM Facility at Imperial College London for the use of the microscopes and their technical support.

### **Sources of Funding:**

This work was supported by a project grant from the British Heart Foundation (BHF) to JAM (PG/16/83/32467), a British Pharmacology Society Bulbring Award and Wellcome Trust/Imperial College Institutional Support Fellowship for BA-S, BBSRC grants BB/R013071/1 (TPP, WB) and BB/R007292/1 (LB, WB) and Wellcome Trust grant 205100 (WB). JAM is a holder of a program grant from the British Heart Foundation (RG/18/4/33541). OCS was supported by a Wellcome Trust studentship.

### **Disclosures:**


The authors have no disclosures to declare.

## References:


1. Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults.
2. Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ, Gordijn SJ, Bolling MC, Dijkstra G, Voors AA, Osterhaus AD, van der Voort PH, Mulder DJ and van Goor H. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). *J Pathol.* 2020;251:228-248.
3. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Muller MA, Drosten C and Pohlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell.* 2020;181:271-280 e8.
4. Ulrich H and Pillat MM. CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement. *Stem Cell Rev Rep.* 2020.
5. Wang K, Chen W, Zhou YS, Lian JQ, Zhang Z, Du P, Gong L, Zhang Y, Cui HY, Geng JJ, Wang B, Sun XX, Wang CF, Yang X, Lin P, Deng YQ, Wei D, Yang XM, Zhu YM, Zhang K, Zheng ZH, Miao JL, Guo T, Shi Y, Zhang S, Fu L, Wang QY, Bian H, Zhu P and Chen ZN. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. *BioRxiv preprint* 2020.
6. Shilts J and Wright GJ. No evidence for basigin/CD147 as a direct SARS-CoV-2 spike binding receptor. *bioRxiv.* 2020.
7. Sungnak W, Huang N, Becavin C, Berg M, Queen R, Litvinukova M, Talavera-Lopez C, Maatz H, Reichart D, Sampaziotis F, Worlock KB, Yoshida M, Barnes JL and Network HCALB. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. *Nat Med.* 2020;26:681-687.
8. Marshall M. The lasting misery of coronavirus long-haulers. *Nature.* 2020;585:339-341.
9. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, Bikdeli B, Ahluwalia N, Ausiello JC, Wan EY, Freedberg DE, Kirtane AJ, Parikh SA, Maurer MS, Nordvig AS, Accili D, Bathon JM, Mohan S, Bauer KA, Leon MB, Krumholz HM, Uriel N, Mehra MR, Elkind MSV, Stone GW, Schwartz A, Ho DD, Bilezikian JP and Landry DW. Extrapulmonary manifestations of COVID-19. *Nat Med.* 2020;26:1017-1032.
10. Libby P and Luscher T. COVID-19 is, in the end, an endothelial disease. *Eur Heart J.* 2020;41:3038-3044.
11. Huertas A, Montani D, Savale L, Pichon J, Tu L, Parent F, Guignabert C and Humbert M. Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)? *Eur Respir J.* 2020.
12. Monteil V, Kwon H, Prado P, Hagelkruys A, Wimmer RA, Stahl M, Leopoldi A, Garreta E, Hurtado Del Pozo C, Prosper F, Romero JP, Wirnsberger G, Zhang H, Slutsky AS, Conder R, Montserrat N, Mirazimi A and Penninger JM. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. *Cell.* 2020;181:905-913 e7.
13. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F and Moch H. Endothelial cell infection and endotheliitis in COVID-19. *Lancet.* 2020;395:1417-1418.
14. Miller SE and Goldsmith CS. Caution in Identifying Coronaviruses by Electron Microscopy. *J Am Soc Nephrol.* 2020;31:2223-2224.
15. Ahmetaj-Shala B, Vaja R, Atanur SS, George PM, Kirkby NS and Mitchell JA. Cardiorenal tissues express SARS-CoV-2 entry genes and basigin (BSG/CD147) increases with age in endothelial cells. *JACC Basic Transl Sci.* 2020.

16. Ahmetaj-Shala B, Kawai R, Marei I, Nikolakopoulou Z, Shih CC, Konain B, Reed DM, Mongey R, Kirkby NS and Mitchell JA. A bioassay system of autologous human endothelial, smooth muscle cells, and leukocytes for use in drug discovery, phenotyping, and tissue engineering. *FASEB J.* 2020;34:1745-1754.
17. Peacock TP, Goldhill DH, Zhou J, Baillon L, Frise R, Swann OC, Kugathasan R, Penn R, Brown JC, Sanchez-David RY, Braga L, Williamson MK, Hassard JA, Staller E, Hanley B, Osborn M, Giacca M, Davidson AD, Matthews DA and Barclay WS. The furin cleavage site of SARS-CoV-2 spike protein is a key determinant for transmission due to enhanced replication in airway cells. *bioRxiv.* 2020:2020.09.30.318311.
18. McKay PF, Hu K, Blakney AK, Samnuan K, Brown JC, Penn R, Zhou J, Bouton CR, Rogers P, Polra K, Lin PJC, Barbosa C, Tam YK, Barclay WS and Shattock RJ. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. *Nat Commun.* 2020;11:3523.
19. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K, Tomancak P and Cardona A. Fiji: an open-source platform for biological-image analysis. *Nat Methods.* 2012;9:676-82.
20. Harcourt BH, Sanchez A and Offermann MK. Ebola virus inhibits induction of genes by double-stranded RNA in endothelial cells. *Virology.* 1998;252:179-88.
21. Fu Y, Cheng Y and Wu Y. Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools. *Virol Sin.* 2020;35:266-271.

**Figures:**




**Figure 1: mRNA expression of *ACE2*, *TMPRSS2*, *BSG*, *PPIA* and *PPIB* in human nasal epithelial cells (NEC) and endothelial cells (aortic, microvascular and blood outgrowth).** Expression levels for the genes *ACE2*, *TMPRSS2*, *BSG*, *PPIA* and *PPIB* were obtained from aortic (AoEC), microvascular (HMVEC) and blood outgrowth (BOEC) endothelial cells and nasal epithelial cells (NEC). Data for each donor were normalised using the average of the housekeepers (18S and Gapdh) and analysed using a comparative Ct method ( $2^{-\Delta\Delta Ct}$ ). Data are shown as the mean  $\pm$  SEM fold change compared to nasal epithelium (n=3 wells using cells from 2 donors) for AoEC (n=3 wells using cells of 3 separate donors), HMVEC ((n=3 wells using cells of 3 separate donors and BOECs (n=2 wells using cells of 2 separate donors).



**Figure 2: SARS-CoV-2 live virus infection in human airway epithelial cells in air:liquid interface, Vero E6 and endothelial cells**


Human airway epithelial cells grown in an air:liquid interface environment from MucilAir™ were infected with SARS-CoV-2 live virus (MOI 0.1) and the plaque forming units (measure of infectious virus obtained from permissive cells) was determined over time (6, 24, 48 and 72 hours post-infection). In separate studies, the levels of SARS-CoV-2 nucleocapsid or spike

protein in Vero E6 and endothelial cells (treated with media only (untreated) or IL-1 $\beta$  (10ng/ml; 3hrs)) at 24 (B) and 72 (C) hours post infection with SARS-CoV-2 (MOI 0.1) were determined using florescent imaging. Mock controls (media only) experiments were run simultaneously using each endothelial cell line. Data is shown as n=3 (pooled donors) for Mucilair cells (A) and n=3 (separate donors) for human aortic (AoEC), lung microvascular (HMVEC) and blood outgrowth endothelial cells (BOEC). Data are shown as mean +/- SEM for panel A and representative images shown for panel A and representative images for panels B and C.



**Figure 3: Pseudovirus infection with SARS-CoV-2 (A), vesicular stomatitis virus G (VSV-G) (B), Ebola (C) in endothelial cells or SARS-CoV-2 in kidney embryonic kidney (HEK 293T) cells transfected with ACE2 or BSG (D).**

SARS-CoV-2 (A) and VSV-G and Ebola (B) pseudovirus levels were measured using a Luciferase Assay System 48 hours post-transduction. Data were from n=12 wells using cells from 3 donors separate donors in experiments performed on 2 separate occasions for aortic (AoEC), microvascular (HMVEC) and blood outgrowth (BOEC) (A-C); ACE2-HEK-2932T and BSG-HEK-2932T are n=3. Data are expressed as individual values and as mean  $\pm$  SEM. Dotted lines on graphs indicate background signal as determined by the mean of control/bald (no cells or empty).



**Figure 4: Susceptibility of endothelial cells treated with IL-1 $\beta$  to pseudoviruses expressing SARS-CoV-2 spike (A), vesicular stomatitis virus glycoprotein (VSV-G) (B) or Ebola glycoprotein (C).**


SARS-CoV-2 (A) and VSV-G and Ebola (B) pseudovirus entry was measured using a Luciferase Assay System 48 hours post infection in endothelial cells treated with IL-1 $\beta$  (10 ng/ml) for 3 hours prior to infection. Data were from n=6 wells from n=3 donors of endothelial cells; aortic (AoEC), microvascular (HMVEC) and blood outgrowth (BOEC). Data are expressed as individual values and mean  $\pm$  SEM. Dotted lines on graphs indicate background signal as determined by the mean of control/bald (no cells).

## Supplementary Tables and Figures

Gene	Cell type	Raw CT values		
		1	2	3
<i>ACE2</i>	AoEC	38.3	37.5	36.2
	HMVEC	Undet.	Undet.	Undet.
	BOEC	Undet.	39.3	N/A
	NEC	31.3	31.2	30.7
<i>TMPRSS2</i>	AoEC	Undet.	Undet.	Undet.
	HMVEC	Undet.	Undet.	Undet.
	BOEC	Undet.	Undet.	Undet.
	NEC	29.2	27.6	27.5
<i>BSG</i>	AoEC	20.2	20.3	21.2
	HMVEC	23.2	24.3	21.0
	BOEC	23.4	20.4	N/A
	NEC	20.4	21.4	20.2
<i>PPIA</i>	AoEC	23.7	22.0	22.5
	HMVEC	23.9	23.6	22.8
	BOEC	24.1	22.0	N/A
	NEC	22.1	23.1	22.5
<i>PPIB</i>	AoEC	20.6	21.0	21.2
	HMVEC	24.1	24.0	22.2
	BOEC	24.2	21.2	N/A
	NEC	21.4	21.7	21.3
<i>18S/GAPDH</i>	AoEC	17.8	17.3	17.1
	HMVEC	19.1	20.0	17.9
	BOEC	21.0	16.7	N/A
	NEC	18.1	17.2	17.3


### Supplementary Table 1: Average raw Ct values from qRT-PCR

Expression levels (Ct) for the genes *ACE2*, *TMPRSS2*, *BSG*, *PPIA* and *PPIB* were obtained from aortic (AoEC), microvascular (HMVEC) and blood outgrowth (BOEC) endothelial cells and nasal epithelial cells (NEC). Data for each donor were corrected using the average of the housekeepers (*18S* and *GAPDH*) and analysed using a comparative Ct method ( $2^{-\Delta\Delta Ct}$ ). Data are shown as the mean +/- from n=3 wells using cells from 3 separate donors for AoEC and HMVEC and n=3 wells using cells from 2 separate donors for NEC and n=2 wells from 2 separate for BOECs.




### Supplementary Figure 1. Blind scoring of SARS-CoV-2 live virus infection in Vero E6 and endothelial cells

Levels of SARS-CoV-2 nucleocapsid and spike protein in Vero E6 and endothelial cells at 24 and 72 hours post infection with SARS-CoV-2 (MOI 0.1) in untreated (A-B) and IL-1 $\beta$  (10ng/ml; 3 hours) (C-D) were determined using florescent imaging. One representative image was taken and blinded images were scored between 1-5, where 1= 0-2, 2= 3-5, 3= 6-8, 4= 9-10 and 5= >10 virus nucleocapsin/spike protein staining. Data are shown as individual scores for n=3 (separate donors) for human aortic (AoEC), lung microvascular (HMVEC) and blood outgrowth endothelial cells (BOEC) and n=1 for Vero E6 cells (untreated).



**Supplementary Figure 2: ACE2 and BSG protein expression in HEK 239Ts.**

Overexpression of ACE2-FLAG and CD147/BSG in HEK 293T cells was confirmed by western blot.



**Supplementary Figure 3: Effect of IL-1 $\beta$  on release of IL-6 and IL-8 from endothelial cells**

Human endothelial cells (aortic; AoEC, lung microvascular; HMVEC, and blood outgrowth; BOEC) were treated for 3 hours with IL-1 $\beta$  (10ng/ml) before media was replaced with fresh media (EGM-2, 2% FBS) for 24 hours. Media was collected and IL-6 and IL-8 levels measured using ELISA. Data are shown as individual values and mean  $\pm$  from n=3 wells using cells from 3 separate donors for AoEC and HMVEC and n=6 wells from 3 separate donors for BOECs.